Simone Claudiani, MD

Introducing next generation sequencing for the diagnosis of myeloproliferative neoplasms (MPN)

We wish to improve the accuracy and cost-effectiveness of tests to diagnose the pre-malignant and malignant blood cancers, known as the myeloproliferative disorders (MPD). Together with two other large UK clinics, we will assess modern techniques (next generation sequencing) as a replacement for the current laborious and costly laboratory assays.